Mavyret OverviewGlecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in Europe) is a combination drug containing glecaprevir (100mg) and pibrentasvir (40mg). In the United States, it was approved by the Food and Drug Administration in August 2017 for treatment of hepatitis C. In Europe, it was also approved in August 2017 for the same indication. Contents 1 Medical uses 2 Side effects 3 Clinical trials 4 Development 5 References Medical uses Mavyret is the brand name a combina...
Read more Mavyret Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glecaprevir/pibrentasvir
Recent Mavyret Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
Glecaprevir + Pibrentasvir
- Tablet: 100mg + 40mg
NDC Database Records for Mavyret: (1 result)Sorted by National Drug Code
- 0074-2625 Mavyret Oral Tablet, Film Coated by Abbvie Inc.